Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

Phase 2

Completed

Conditions: Age Related Macular Degeneration

Interventions: Drug: 0.5 mg ranibizumab
Drug: 1 mg PF-04523655
Drug: 3 mg PF-04523655

Registration Number: NCT00713518

Lead Sponsor: Quark Pharmaceuticals

Brief Summary: The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 152

Inclusion Criteria

Males and females age 50 years or older with active primary or recurrent subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Active CNV is defined as any leakage detected on FFA or OCT. Note: Female subjects 50- 60 years of age must be amenorrheic for at least 2 years and have a serum FSH level within the laboratory reference range for postmenopausal women
The total area of CNV (including both classic and occult components) encompassed within the lesion must be 50% or more of the total lesion area.
The total lesion size ≤12 disc areas.
Best corrected visual acuity using ETDRS protocol of 20/40 to 20/320 (letter score ≤73) in the study eye at the screening visit.
Best corrected visual acuity score in the fellow eye of 20/400 or better (letter score of ≥19) at the Screening Visit. Note: Only one eye will be treated (study eye) through the duration of the study. In the event both eyes are eligible for study entry the study eye should be selected by the investigator and subject. The non-study eye may be treated with an approved AMD therapy
Subject has retinal central subfield thickness ≥250µm measured using Stratus OCT.

Exclusion Criteria

Prior treatment with verteporfin photodynamic therapy, external-beam radiation therapy, or transpupillary thermotherapy in the study eye
Previous subfoveal focal laser photocoagulation in the study eye
Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding Baseline
History of vitrectomy, submacular surgery or other surgical intervention for AMD in the study eye
Previous participation in any studies with investigational drugs or treatments administered 1 month preceding Baseline visit such as systemic glucocorticoids, ocular or periocular steroids (eg, triamcinolone, anecortave acetate), anti-angiogenic drugs such as pegaptanib (Macugen), ranibizumab (Lucentis), bevacizumab (Avastin) in the study eye
Subretinal hemorrhage in the study eye that involves the fovea, if the size of the hemorrhage is either 50% or more of the total lesion area or 1 or more disc areas in size
CNV in either eye of other etiology, eg, ocular histoplasmosis, trauma, or pathologic myopia
Presence of subfoveal scarring
Retinal pigment epithelial tear involving the macula in the study eye

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm 1 ranibizumab	0.5 mg ranibizumab	0.5 mg ranibizumab intravitreal injection given every 4 weeks from baseline to Week 12
Arm 4 ranibizumab and PF-04523655	0.5 mg ranibizumab	0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg of PF-04523655 given by intravitreal injection every 4 weeks from Week 4 to Week 12
Arm 5 ranibizumab and PF-04523655	0.5 mg ranibizumab	0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg of PF-04523655 (30 minutes later) given in combination every 4 weeks from baseline to Week 12
Arm 5 ranibizumab and PF-04523655	1 mg PF-04523655	0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg of PF-04523655 (30 minutes later) given in combination every 4 weeks from baseline to Week 12
Arm 2 ranibizumab and PF-04523655	0.5 mg ranibizumab	0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg PF-04523655 given by intravitreal injection every 2 weeks from Week 4 to Week 12
Arm 2 ranibizumab and PF-04523655	3 mg PF-04523655	0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg PF-04523655 given by intravitreal injection every 2 weeks from Week 4 to Week 12
Arm 3 ranibizumab and PF-04523655	0.5 mg ranibizumab	0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg PF-04523655 given by intravitreal injection evey 4 weeks to Week 12
Arm 3 ranibizumab and PF-04523655	1 mg PF-04523655	0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg PF-04523655 given by intravitreal injection evey 4 weeks to Week 12
Arm 4 ranibizumab and PF-04523655	3 mg PF-04523655	0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg of PF-04523655 given by intravitreal injection every 4 weeks from Week 4 to Week 12

Primary Outcome Measures

Name	Time	Method
Mean change in the best corrected visual acuity score measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol by Week 16	Week 16

Secondary Outcome Measures

Name	Time	Method
Percent of subjects gaining >/=15 letters in the best corrected visual acuity score at 16 weeks compared to Baseline, as measured using the ETDRS protocol	Week 16
Mean change from Baseline over time (16 weeks) in the best corrected visual acuity score, as measured using the ETDRS protocol	Week 16
Incidence and severity of ocular adverse events identified by ophthalmic examination and or spontaneously reported	Week 48
Change from Baseline to Weeks 4,8, 12, and 16 in retinal central subfield thickness and retinal lesion thickness assessed by OCT	Week 16
Incidence and severity of systemic adverse events identified by physical examination, changes in vital signs, clinical laboratory abnormalities and or spontaneously reported	Week 48
Change from Baseline in lesion size on FFA at Week 16	Week 16